IDiyas

For the Inventor, By the Inventor

Lawrenceville, NJ, United States of America

Peter R Young

USPTO Granted Patents = 29

 

Average Co-Inventor Count = 2.9

ph-index = 11

Forward Citations = 433(Granted Patents)


Location History:

  • New Jersey, NJ (US) (1999)
  • US (1999 - 2000)
  • Laurenceville, NJ (US) (2002)
  • St Davids, PA (US) (2002)
  • Lawrenceville, NJ (US) (1998 - 2006)
  • Wilmington, DE (US) (2006)
  • Guilford, CT (US) (2020 - 2022)

Company Filing History:

goldMedal25 out of 2,198 
 
Smithkline Beecham Corporation
 patents
silverMedal2 out of 14 
 
Ai Therapeutics, Inc.
 patents
bronzeMedal1 out of 1 
 
Smithkline Beecham Corporation, Et Al.
 patent
4. 2 out of 832,680 
Other
 patents
where one patent can have more than one assignee

Years Active: 1998-2022

Loading Chart...
Loading Chart...
29 patents (USPTO):Explore Patents
1. 11439649 - Combination therapy with apilimod and glutamatergic agents (2022-09-13),
2. 10751345 - Combination therapy with apilimod and glutamatergic agents (2020-08-25),
3. 7049422 - Tumor necrosis related receptor, TR7 (2006-05-23),
4. 6998124 - Erythropoietin receptor antibodies (2006-02-14),
5. 6660839 - Tumor necrosis related receptor, TR7 (2003-12-09),
6. 6399573 - Interleukin-1 receptor antagonist beta (IL-1rabeta) (2002-06-04),
7. 6361773 - Antibodies produced against cytokine suppressive anti-inflammatory drug binding proteins (2002-03-26),
8. 6346388 - Method of identifying agonist and antagonists for tumor necrosis related receptors TR1 and TR2 (2002-02-12),
9. 6342371 - Interleukin-1 homologue, IL-1H4 (2002-01-29),
10. 6313269 - Tumor necrosis factor related receptor, TR6 (2001-11-06),
11. 6297359 - Protein phosphatase 1 binding protein, R5 (2001-10-02),
12. 6297022 - Method of identifying agonists and antagonists for tumor necrosis related receptor TR1 (2001-10-02),
13. 6245550 - Cytokine family member EF-7 (2001-06-12),
14. 6218136 - Methods of the identification of pharmaceutically active compounds (2001-04-17),
15. 6153190 - Erythropoietin receptor antibodies (2000-11-28),

Title: The Innovative Contributions of Peter R. Young

Introduction: Peter R. Young is a notable inventor based in Lawrenceville, NJ, with an impressive portfolio of 29 patents. His work primarily focuses on innovative therapies aimed at treating neurological diseases and disorders, as well as cancer.

Latest Patents: Among his most recent patents is a combination therapy that incorporates apilimod and glutamatergic agents. This groundbreaking composition presents methods for utilizing apilimod alongside glutamatergic agents for effective treatment in several medical fields.

Career Highlights: Peter R. Young has built a remarkable career contributing to the pharmaceutical industry. He has worked at SmithKline Beecham Corporation, where he made significant strides in the development of therapeutic solutions. His wealth of experience and dedication has paved the way for innovative breakthroughs in drug development.

Collaborations: Throughout his career, Peter has collaborated with esteemed colleagues, including Peter C. McDonnell and Dean E. McNulty. These partnerships have played a crucial role in advancing research in the areas of neurobiology and oncology.

Conclusion: Peter R. Young stands out as a leading inventor in the pharmaceutical domain, with a significant impact on the treatment of various diseases. His innovative patents and collaborative efforts continue to inspire advancements in the medical field, marking him as a prominent figure in contemporary research and development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…